Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.

@article{Matous2009BortezomibBA,
  title={Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.},
  author={Jeffrey V. Matous and Jeffrey P Letzer and Peter Newman Rosen and S Noga and Nathan Fowler and Scott E. Smith and Bipinkumar Amin and Hongliang Shi and Sudha Parasuraman and Bruce D Cheson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={8550}
}
8550 Background: FL is an incurable indolent B-cell non-Hodgkin's lymphoma. Survival has improved in the past decade with the introduction of rituximab (Rituxan, R), but response decreases with repeated exposure. Bortezomib (Velcade, V) plus R was active and generally well tolerated in rel/ref FL [de Vos ASH 2006 Abs694], and bendamustine hydrochloride (Treanda, B) plus R has also shown activity in heavily pretreated FL [Robinson JCO 2008]. The current single-arm, multi-center study evaluates… CONTINUE READING

Similar Papers

Loading similar papers…